Evidence map›Paper›PMID 35722100›Full record

ArticleFrontiers in cardiovascular medicine2022

A Tryptophan Metabolite of the Microbiota Improves Neovascularization in Diabetic Limb Ischemia.

Xiurui Ma, Jinjing Yang, Guanrui Yang, Lei Li, Xiaojun Hao, Guoqin Wang, Jian An, Fei Wang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. A probiotic for preventing microplastic toxicity:Current research in food science · 2025
    Article
  4. Review
  5. Tryptophan intrinsic fluorescence from wound healing correlates with re-epithelialization in a rabbit model.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xiurui MaDepartment of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, China.
Jinjing YangDepartment of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, China.
Guanrui YangDepartment of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, China.
Lei LiDepartment of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, China.
Xiaojun HaoDepartment of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, China.
Guoqin WangDepartment of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, China.
Jian AnDepartment of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, China.
Fei WangDepartment of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, China.
Shanxi Cardiovascular Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) is accompanied by a series of macrovascular and microvascular injuries. Critical limb ischemia is the most severe manifestation of peripheral artery disease (PAD) caused by DM and is almost incurable. Therapeutic modulation of angiogenesis holds promise for the prevention of limb ischemia in diabetic patients with PAD. However, no small-molecule drugs are capable of promoting diabetic angiogenesis. An endogenous tryptophan metabolite, indole-3-aldehyde (3-IAld), has been found to have proangiogenic activity in endothelial cells. Nevertheless, the role of 3-IAld in diabetic angiogenesis remains unknown. Here, we found that 3-IAld ameliorated high glucose-induced mitochondrial dysfunction, decreasing oxidative stress and apoptosis and thus improving neovascularization.

Indexed as

apoptosisdiabetes mellitusindole-3-aldehydelimb ischemiamitochondrial dysfunctionoxidative stress

Identifiers

PMID35722100
PMCPMC9200987
OpenAlexW4281678328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.